HEALTH● LOWAug 14 · Aug 14, 2026, 5:28 AM
Kyntra Bio targets FG-3246 median rPFS of 10 months or greater as it plans roxadustat Phase III start in Q4 2026
Seeking Alpha Tech
Kyntra Bio aims for a median rPFS of 10 months or more for FG-3246 and plans to begin a Phase III trial for roxadustat in Q4 2026. This indicates developments in the company's drug pipeline and clinical trial schedule.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH27m agoAmerica’s vaccine system is an operations failure waiting to happenThe HillHEALTH1h agoPope Leo cancels planned trip on doctors' advice after cancer surgeryThe Independent WorldHEALTH1h agoFrom education to cancer care: Global summit calls for better support for childrenEuroNews [en]HEALTH2h agoPope Leo XIV cancels Assisi trip on doctors' advice as he recovers from surgeryEuroNews [en]